Puma Biotechnology Inc.

Puma Biotechnology develops and commercializes oral neratinib (NERLYNX) for early-stage HER2+ breast cancer and advanced HER2+ disease, plus alisertib for hormone‑positive breast and other solid tumors, backed by a Pfizer license and several strategic sub‑license agreements.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 172
HQ: Los Angeles

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
PBYI	Puma Biotechnology Inc. Cap: 0.3B \| P/E: 8.3	EQUITY	NMS	USD	US74587V1070	Active	📈